Catalyst
Slingshot members are tracking this event:
Bristol-Myers Squibb (BMY) Presents Data From Phase 3 CheckMate -026 Evaluating Opdivo Monotherapy Versus Chemotherapy in First-Line Treatment of Broad PD-L1 Positive Advanced Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 09, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Checkmate -026, Opdivo, Monotherapy, Chemotherapy, First-line, Broad Pd-l1 Positive, Advanced Lung Cancer
